Kiniksa Appoints New CEO, Dr. Sanj K. Patel

TL;DR

Kiniksa gets a new CEO, Dr. Patel, starting Oct 14th. Gaynor moves to CMO.

AI Summary

Kiniksa Pharmaceuticals International, plc announced on October 7, 2024, that Dr. Sanj K. Patel will be appointed as Chief Executive Officer and a member of the Board of Directors, effective October 14, 2024. Dr. Patel will succeed Dr. Richard B. Gaynor, who will transition to the role of Chief Medical Officer. Dr. Patel's employment agreement includes an annual base salary of $650,000 and potential for an annual bonus of up to 75% of his base salary.

Why It Matters

The appointment of a new CEO and the transition of the current CEO to a different role signals a potential shift in leadership strategy and focus for Kiniksa Pharmaceuticals.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Numbers

• $650,000 — CEO Base Salary (Dr. Sanj K. Patel's starting annual base salary.)
• 75% — CEO Bonus Potential (Maximum annual bonus Dr. Patel can receive as a percentage of his base salary.)

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Registrant
• Dr. Sanj K. Patel (person) — Incoming Chief Executive Officer and Board Member
• Dr. Richard B. Gaynor (person) — Outgoing Chief Executive Officer, transitioning to Chief Medical Officer
• $650,000 (dollar_amount) — Dr. Patel's annual base salary
• 75% (dollar_amount) — Maximum annual bonus percentage for Dr. Patel
• October 14, 2024 (date) — Effective date of Dr. Patel's appointment
• October 7, 2024 (date) — Date of the report
• October 4, 2024 (date) — Earliest event reported

FAQ

Key Financial Figures

• $0.000273235 — h registered Class A Ordinary Shares $0.000273235 nominal value KNSA The Nasdaq Stock
• $120,000 — the amount involved exceeds or exceeded $120,000. Ms. Boyd will receive standard non-e

Filing Documents

• tm2425633d1_8k.htm (8-K) — 27KB
• 0001104659-24-106690.txt ( ) — 195KB
• knsa-20241004.xsd (EX-101.SCH) — 3KB
• knsa-20241004_lab.xml (EX-101.LAB) — 33KB
• knsa-20241004_pre.xml (EX-101.PRE) — 22KB
• tm2425633d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain Officers;

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 4, 2024, the Board of Directors (the "Board") of Kiniksa Pharmaceuticals International, plc (the "Company") approved an increase in the number of directors constituting the Board from nine (9) to ten (10) directors and the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby. Ms. Boyd was appointed as a member of the Class III directors, joining Felix J. Baker, Ph.D., Tracey L. McCain and Kimberly J. Popovits and will serve for the same periods as the Board's other Class III directors or until her earlier death, resignation or removal. Ms. Boyd was also appointed by the Board to serve on the Board's Compensation Committee in connection with her appointment to the Board. Ms. Boyd currently serves as a Managing Director of Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. Prior to joining Baker Bros. Advisors LP in 2005, she was an Analyst in the Health Care Investment Banking Group of Deutsche Bank Securities from 2002 to 2004. Ms. Boyd graduated with an AB in Business-Economics from Brown University. The Board believes that Ms. Boyd's extensive experience in the life sciences industry, along with her financial and business acumen, will be a significant benefit to the Company. There are no arrangements or understandings between either Ms. Boyd, on the one hand, and any other person, on the other hand, pursuant to which she was appointed to the Board. Since the beginning of the Company's last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which Ms. Boyd was or is to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Date: October 7, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary